|Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin …|
TM Green, KH Young, C Visco, ZY Xu-Monette, A Orazi, RS Go, O Nielsen, ...
J Clin Oncol 30 (28), 3460-3467, 2012
|MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression …|
S Hu, ZY Xu-Monette, A Tzankov, T Green, L Wu, A Balasubramanyam, ...
Blood, The Journal of the American Society of Hematology 121 (20), 4021-4031, 2013
|Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large …|
C Visco, Y Li, ZY Xu-Monette, RN Miranda, TM Green, A Tzankov, W Wen, ...
Leukemia 26 (9), 2103-2113, 2012
|The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation|
D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ...
Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011
|Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP …|
ZY Xu-Monette, L Wu, C Visco, YC Tai, A Tzankov, W Liu, ...
Blood, The Journal of the American Society of Hematology 120 (19), 3986-3996, 2012
|Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia|
D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ...
Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015
|CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL …|
S Hu, ZY Xu-Monette, A Balasubramanyam, GC Manyam, C Visco, ...
Blood, The Journal of the American Society of Hematology 121 (14), 2715-2724, 2013
|Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation|
C Visco, S Finotto, R Zambello, R Paolini, A Menin, R Zanotti, F Zaja, ...
Journal of clinical oncology 31 (11), 1442-1449, 2013
|Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study|
F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ...
The Lancet Haematology 7 (10), e737-e745, 2020
|Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International …|
C Visco, A Tzankov, ZY Xu-Monette, RN Miranda, YC Tai, Y Li, W Liu, ...
Haematologica 98 (2), 255, 2013
|Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi|
L Arcaini, D Vallisa, S Rattotti, VV Ferretti, AJM Ferreri, P Bernuzzi, ...
Annals of oncology 25 (7), 1404-1410, 2014
|Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo …|
F Merli, S Luminari, F Ilariucci, M Petrini, C Visco, A Ambrosetti, ...
British journal of haematology 156 (3), 346-353, 2012
|Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP|
A Tzankov, ZY Xu-Monette, M Gerhard, C Visco, S Dirnhofer, N Gisin, ...
Modern pathology 27 (7), 958-971, 2014
|Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection|
L Arcaini, C Besson, M Frigeni, H Fontaine, M Goldaniga, M Casato, ...
Blood, The Journal of the American Society of Hematology 128 (21), 2527-2532, 2016
|Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia|
C Visco, M Ruggeri, M Laura Evangelista, R Stasi, R Zanotti, I Giaretta, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1110-1116, 2008
|Prevalence and clinical implications of Epstein–Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries|
CY Ok, L Li, ZY Xu-Monette, C Visco, A Tzankov, GC Manyam, ...
Clinical Cancer Research 20 (9), 2338-2349, 2014
|Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease|
A Tedeschi, G Benevolo, M Varettoni, ML Battista, PL Zinzani, C Visco, ...
Cancer 118 (2), 434-443, 2012
|Autoimmune cytopenias in chronic lymphocytic leukemia|
C Visco, W Barcellini, F Maura, A Neri, A Cortelezzi, F Rodeghiero
American journal of hematology 89 (11), 1055-1062, 2014
|Primary plasma cell leukemia: a retrospective multicenter study of 73 patients|
L Pagano, CG Valentini, V De Stefano, A Venditti, G Visani, MT Petrucci, ...
Annals of oncology 22 (7), 1628-1635, 2011
|miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy|
S Montes-Moreno, N Martinez, B Sanchez-Espiridión, R Díaz Uriarte, ...
Blood, The Journal of the American Society of Hematology 118 (4), 1034-1040, 2011